Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TST002 Intervenous Injection in Postmenopausal Women and Men With Reduced Bone Mineral Density

NCT05391776 is registered in ClinicalTrials.gov with HJB (Hangzhou) Co., Ltd. as lead sponsor.

NCT NCT05391776
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05391776 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TST002 Intervenous Injection in Postmenopausal Women and Men With Reduced Bone Mineral Density
Lead sponsor
HJB (Hangzhou) Co., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
April 28, 2022
Completion date
June 28, 2023
Enrollment
32 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

osteoporosis